Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. It also has weak beta-adrenergic activity.
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Relief of symptoms of seasonal allergic rhinitis (sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes),Relief of nasal congestion associated with seasonal allergic rhinitis,Relief of symptoms of perennial allergic rhinitis,Relief of nasal congestion associated with perennial allergic rhinitis
Moderate to severe pain where an opioid analgesic is appropriate
1 tablet (fexofenadine 180 mg / pseudoephedrine 240 mg) orally every 24 hours.
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
Fexofenadine: terminal half-life 14.4 hours (range 11-17 h, ~4-fold longer than IV due to enterohepatic recirculation); pseudoephedrine: terminal half-life 4.3-8 hours (alkaline urine prolongs to 16 h).
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Fexofenadine is minimally metabolized (≤5% of dose) by the liver, primarily via CYP3A4; other minor pathways involve CYP2D6 and CYP2C9. Pseudoephedrine is partially metabolized in the liver by N-demethylation (CYP2D6) and oxidative deamination.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Fexofenadine: ~95% excreted unchanged in feces (80%) and urine (11-12%); pseudoephedrine: ~70-90% excreted unchanged in urine (major route).
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Fexofenadine: 60-70% primarily to albumin and α1-acid glycoprotein; pseudoephedrine: negligible protein binding (<20%, mainly to albumin).
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Fexofenadine: 5.4-5.8 L/kg (extensive tissue distribution, ~30-40 times plasma volume); pseudoephedrine: 2.6-3.5 L/kg (distributes into body water, crosses blood-brain barrier).
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Fexofenadine: ~33-40% (oral, decreased by fruit juices); pseudoephedrine: ~85-100% (oral, minimally affected by food).
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
GFR 30-49 m L/min: 1 tablet every 24 hours; GFR 15-29 m L/min: 1 tablet every 48 hours; GFR <15 m L/min: contraindicated or not recommended.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C); use with caution.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
Not recommended for children under 12 years. For age >=12 years: same as adult dosing (1 tablet every 24 hours).
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
Elderly patients may have reduced renal function; assess renal function prior to use. Initial dose may be adjusted based on renal function. Avoid use in patients with hypertension or cardiovascular disease due to pseudoephedrine.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
None
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Cardiovascular effects (hypertension, palpitations, tachycardia, arrhythmias) especially in patients with pre-existing cardiovascular disease; CNS stimulation (insomnia, nervousness, dizziness, anxiety); risk of ischemic colitis; urinary retention (especially in patients with prostatic hypertrophy); increased intraocular pressure in patients with narrow-angle glaucoma; severe hypertension or coronary artery disease; MAOI use or within 14 days of discontinuation; use in renal impairment requires caution; avoid use with alcohol or other CNS depressants; caution in patients with hyperthyroidism, diabetes mellitus, or angle-closure glaucoma; elderly patients may be more sensitive to side effects.
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Concurrent use of or within 14 days after discontinuation of monoamine oxidase inhibitors (MAOIs); severe hypertension; severe coronary artery disease; narrow-angle glaucoma; urinary retention; hypersensitivity to any component
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Fruit juices (apple, orange, grapefruit) significantly reduce fexofenadine absorption; take with water only. Avoid high-fat meals as they may affect pseudoephedrine absorption. No specific restrictions for pseudoephedrine, but avoid excessive caffeine (coffee, tea, cola) to reduce additive stimulant effects.
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
FDA Pregnancy Category C. First trimester: No adequate studies, animal studies show potential risk. Second and third trimesters: Risk unknown; associated with increased risk of gastrointestinal atresia and gastroschisis with first trimester pseudoephedrine use. Avoid in preeclampsia due to vasoconstriction.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Lactation Risk Category L3 (Moderately Safe). Fexofenadine excreted in breast milk in low amounts; M/P ratio not established. Pseudoephedrine excreted into breast milk with estimated relative infant dose 4.3% of maternal weight-adjusted dose. May reduce milk production and cause irritability in infants.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
Pregnancy increases clearance of fexofenadine; however, no specific dose adjustment recommended. Dose of pseudoephedrine should be limited to lowest effective dose due to potential vasoconstriction. Avoid extended-release formulations in pregnancy if rapid delivery is anticipated.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION contains fexofenadine 180 mg and pseudoephedrine 240 mg extended-release. Avoid in severe hypertension, coronary artery disease, narrow-angle glaucoma, urinary retention, and concurrent MAOI use or within 14 days. CNS stimulation possible; monitor for insomnia, nervousness, and dizziness. Not recommended in patients with impaired renal function (Cr Cl < 60 m L/min) due to fexofenadine accumulation. Do not crush or chew tablet.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Take one tablet daily with water; do not crush or chew.,Avoid taking with fruit juices (e.g., apple, orange, grapefruit) as they may decrease absorption.,Do not use with other products containing pseudoephedrine or antihistamines.,Stop and consult doctor if symptoms do not improve within 7 days or are accompanied by fever.,Avoid alcohol and sedatives as they may increase dizziness.,Discontinue if signs of hypertension or tachycardia occur.,Contraindicated within 14 days of stopping MAOIs.,Pregnant or nursing women should consult a physician before use.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
No interactions on record
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is a Antihistamine-Decongestant Combination that works by Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. It also has weak beta-adrenergic activity.. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is: 1 tablet (fexofenadine 180 mg / pseudoephedrine 240 mg) orally every 24 hours.. The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies, animal studies show potential risk. Second and third trimesters: Risk unknown; associated with increased risk of gas. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.